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ABSTRACTr: The effect of ivermectin or diethylcarbam- 
azine (DEC) on Wuchereria bancrofti molting from the 
third to the fourth larval stage (L3 to L4) was evaluated 
in vitro. L3 larvae were harvested from laboratory- 
reared Aedes togoi 2 wk after feeding upon a microfi- 
laremic human volunteer. The larvae were kept in an 
artificial medium (Franke's NI medium) with 10% hu- 
man serum under an atmosphere of 5% CO2 for 20 
days. Experimental tubes also contained ivermectin 
(0.1-1,000 ng/ml) or DEC (0.1-10,000 ng/ml). An es- 
timated concentration of 50 ng/ml ivermectin inhib- 
ited molting in 50% of the larvae expected to molt. For 
DEC, this value was roughly 1,000 ng/ml. In this in 
vitro culture system, ivermectin inhibited the L3 to L4 
molt of W. bancrofti and was roughly 20-fold more 
potent in this activity than DEC. 
Humans suffering infection of the dermis and 
conjunctiva by microfilariae of Onchocerca vol- 
vulus have enjoyed marked therapeutic advan- 
tages with ivermectin versus diethylcarbamazine 
(DEC). Although ivermectin and DEC both 
greatly diminish numbers of viable microfilariae, 
ivermectin appears much less likely to elicit the 
potentially maiming and life-threatening Maz- 
zotti reaction that occasionally marks therapy 
with DEC. Ivermectin shares with DEC che- 
moprophylactic activity against Dirofilaria im- 
mitis in dogs (McCall et al., 1984) and against 
Onchocerca lienalis in vitro, i.e., inhibition of L3 
molting (Court et al., 1985; Lok et al., 1987). 
However, Taylor et al. (1988) found that iver- 
mectin failed to prevent infection of chimpan- 
zees by 0. volvulus. In view of a possible che- 
moprophylactic role for ivermectin against 
bancroftian filariasis in humans, we evaluted the 
effects of ivermectin on the molting of L3 larvae 
of Wuchereria bancrofti in vitro. 
Third stage larvae of W. bancrofti were har- 
vested from laboratory-rearedAedes togoi 14 days 
after feeding upon a microfilaremic human vol- 
unteer living in Jakarta, Indonesia. The larvae 
were harvested and cultured as described by 
Franke et al. (1987), except that ivermectin or 
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DEC was added to the culture medium (Frank's 
NI medium with 10% human serum). The drugs 
were present in the culture medium through the 
duration of the experiments. Negative controls 
consisted of at least 2 tubes of 20-25 larvae per 
tube cultured in medium lacking drugs. These 
controls were run with each experiment in which 
effects of drugs were evaluated. Tubes for eval- 
uation of effects of drugs also contained 20-25 
larvae, and for each determination the duplicate 
sets of tubes were run on at least 2 occasions. 
Experiments were terminated after 20 days, soon 
after most control larvae had molted. The per- 
cent molt among drug-treated larvae was cal- 
culated using the following equation, where T 
denotes test condition (i.e., drug present) and C 
denotes negative control: % molt = {L4T - [(L4C 
- (L4C + L3C))(L3T + L4T)]} -100. 
Inclusion of the proportion of negative control 
larvae molting in the denominator of the % molt 
calculation eliminated effects of drug-indepen- 
dent inhibition of molt. In all experiments, this 
proportion ranged between 0.75 and 1.0, i.e., the 
proportion of larvae expected to molt in the ab- 
sence of drug effects. Most L3 larvae in either test 
or control tubes were living when the experiment 
was terminated. Mortality specifically attribut- 
able to drugs was not documented. 
Figure 1 illustrates the dose-dependent inhi- 
bition of molting by ivermectin or DEC. Neither 
drug caused appreciable inhibition below 10 ng/ 
ml. The estimated dose for inhibiting molt among 
half the larvae was 50 ng/ml for ivermectin, and 
1,000 ng/ml for DEC. As much as 500 ng/ml 
ivermectin was required to inhibit molt com- 
pletely, and this occurred only at the highest con- 
centration of DEC (10,000 ng/ml). 
Just what the results in Figure 1 mean in terms 
of how the drugs may act in humans is uncertain. 
There are several distinct concerns in this regard, 
foremost among them are questions regarding 
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FIGURE 1. Molting of the third stage larva (L3) of 
Wuchereria bancrofti in vitro in the presence of in- 
creasing concentrations of ivermectin or diethylcar- 
bamazine (DEC). Each point is the mean of at least 2 
replicates measured on 2 occasions. The line drawn for 
each drug is a best-fit curve. 
activity of metabolites of ivermectin versus par- 
ent. Fink and Porras (1989) found that appre- 
ciable proportions of ivermectin were metabo- 
lized rapidly (<5 hr) and that after a single 
therapeutic dose, metabolites persisted at about 
50 ng/ml human plasma for at least 3 days where- 
as less than 5 ng parent ivermectin remained per 
ml plasma after just 24 hr. From the pharmo- 
kinetic point of view, hope for chemoprophy- 
lactic activity of ivermectin lies in its longer lived 
metabolites. Another concern is the possibility 
of sequestration of ivermectin in glass and plas- 
tics as reported by Rew et al. (1986). Unless the 
concentration of drug in the final incubation me- 
dium actually is measured, it is not possible to 
know the concentration available to act upon the 
parasites. 
In summary, we have shown that ivermectin 
inhibits a molt of W. bancrofti that occurs in 
human tissues as part of the development of this 
parasite. Ivermectin was roughly 20-fold more 
effective than DEC in this activity. Studies eval- 
uating the effects of the human metabolic deriv- 
atives of ivermectin are required to evaluate the 
potential of this drug as a chemoprophylactic 
agent against bancroftian filariasis. 
The views of the authors do not purport to 
reflect those of the Department of the Navy or 
the Department of Defense. The authors grate- 
fully acknowledge the support of the Indonesian 
Ministry of Health, especially Dr. Suriadi Gun- 
awan in Jakarta. Also in Jakarta, the authors owe 
a debt of gratitude to Pak Urip. This work was 
supported by the U.S. Naval Medical Research 
and Development Command work unit 
#3M 1 62770A.870.AR42 1. 
LITERATURE CITED 
COURT, J. P., A. E. BLANCO, S. TOWNSON, P. J. HAM, 
AND E. FRIEDHEIM. 1985. Study on the activity 
of antiparasitic agents against Onchocerca lienalis 
third stage larvae in vitro. Tropical Medicine and 
Parasitology 36: 117-119. 
FINK, D. W., AND A. G. PoRRAS. 1989. Pharmoki- 
netics of ivermectin in animals and humans. In 
Ivermectin and abamectin, W. C. Campbell (ed.). 
Springer-Verlag, New York, p. 126-130. 
FRANKE, E. D., W. RIBERU, AND I. WIADY. 1987. In 
vitro cultivation of third stage larvae of Wucher- 
eria bancrofti to the fourth stage. American Jour- 
nal of Tropical Medicine and Hygiene 37: 370- 
375. 
LOK, J. B., R. J. POLLACK, AND J. J. DONNELLY. 1987. 
Studies of the growth-regulating effects of iver- 
mectin on larval Onchocerca lienalis in vitro. Jour- 
nal of Parasitology 73: 80-84. 
MCCALL, J. W., L. M. COWGILL, R. E. PLUE, AND T. 
EVANS. 1984. Prevention of natural acquisition 
of heartworm infection in dogs by monthly treat- 
ment with ivermectin. In Proceedings of the heart- 
worm symposium '83, G. F. Otto (ed.). Veterinary 
Medicine Publishing Co., Edwardsville, Kansas, 
p. 150-152. 
REW, R. S., J. F. URBAN, JR., AND F. W. DouvRES. 
1986. An in vitro screen for anthelmintics using 
larvae of Ascaris suum. American Journal of Vet- 
erinary Research 47: 869-873. 
TAYLOR, H. R., M. TRPIS, E. W. CuPP, B. BROTMAN, 
H. S. NEWLAND, P. T. SOBROSKY, AND B. M. 
GREENE. 1988. Ivermectin prophylaxis against 
experimental Onchocerca volvulus infection in 
chimpanzees. American Journal of Tropical Med- 
icine and Hygiene 59: 86-90. 
